인투셀

287840· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences

₩16,960+1.19%

2026-09-18

Financials

Valuation Metrics

인투셀's Market Cap is ₩2548B. At end of 2025 it was ₩8623B. Ranked #735 of 2,421 in KR market (top 30%), #323 of 1,640 on KOSDAQ (top 20%), #80 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 35%) by Market Cap.

Investment Metrics(as of 2026-09-18)

Metric	Value	Rank
Size
Market Cap	254.77B KRW	KR#735/2,421 Sec#80/231
Revenue	3.19B KRW	KR#2,366/2,421 Sec#203/231
Net Income	-9.45B KRW	KR—/2,421 Sec—/231
Total Assets	36.51B KRW	KR#2,303/2,421 Sec#212/231
Net Assets	19.66B KRW	KR#2,293/2,421 Sec#214/231
Employees	41	KR#2,124/2,421 Sec#196/231
Value
P/B	12.96x	KR#2,377/2,421 Sec#215/231
P/S	79.82x	KR#2,385/2,421 Sec#205/231
FCF Yield	-3.44%	KR—/2,421 Sec—/231
Profitability
ROE	-48.05%	KR#2,272/2,421 Sec#194/231
ROA	-25.87%	KR#2,286/2,421 Sec#192/231
Op. Margin	-279.02%	KR#2,347/2,421 Sec#193/231
Revenue Growth	-20.86%	KR#2,140/2,421 Sec#194/231
Financial Health
Debt Ratio	85.72%	KR#1,422/2,421 Sec#164/231
Total Debt	10.00B KRW	KR#1,624/2,421 Sec#146/231
FCF	-8.77B KRW	KR#1,666/2,421 Sec#141/231
Cash	10.61B KRW	KR#1,659/2,421 Sec#140/231
Current Ratio	1.85x	KR#946/2,421 Sec#105/231
Performance
1Y Return	-54.53%	KR#2,135/2,421 Sec#199/231
1M Return	-17.07%	KR#2,278/2,421 Sec#201/231
From 52W High	-77.36%	KR#2,319/2,421 Sec#210/231
1Y MDD	-80.49%	KR#2,302/2,421 Sec#208/231
Trading
Volume	18,652 shares	KR#1,620/2,421 Sec#158/231
Trading Value	314.1M KRW	KR#1,114/2,421 Sec#114/231
Foreign Own.	4.86%	KR#877/2,421 Sec#78/231
Per Share
EPS	-629 KRW	KR—/2,421 Sec—/231
BPS	1,309 KRW	KR#2,237/2,421 Sec#200/231

Company Info

CEO 박태교

Employees 41

Founded 2015

HQ 대전광역시 대덕구, KR

Website intocell.com

동사는 2015년 약물접합체 기반 바이오신약기술 연구 및 개발을 목적으로 설립되어, 2025년 코스닥시장에 상장함. 항체-약물접합체(ADC) 분야에서 독자적인 OHPAS 링커플랫폼과 PMT 플랫폼 기술을 보유하며, 고유 약물기술을 개발 중임. 링커 플랫폼기술을 이용한 기술수출과 ADC 파이프라인으로 매출을 확보하고, ADC 분야에서 차별화된 솔루션을 제공하고 있음. 인투셀는 2015년에 설립되었으며 대전광역시 대덕구에 본사를 두고 있습니다.